Greenberg Traurig Client Mitoconix Bio to Take Aim at Huntington’s Disease

By Greenberg Traurig on July 10, 2017

Mitoconix Bio, an innovative Israeli startup bred by Israel’s only life science incubator, FutuRx, has recently raised $20 million to develop a promising drug for the treatment of Huntington’s disease and other neurodegenerative disorders, as reported by the Times of Israel.

Both Mitoconix Bio and FutuRx are clients of GT’s Barry Schindler, co-chair…

Tips for Israeli Entrepreneurs Seeking U.S. Investors

By David Gitlin on January 22, 2015

Posted in Emerging Growth Companies, Venture Capital

According to the recently published PwC Israel 2014 Hi-Tech Exit Report, with nearly $15 billion in exit deals, 2014 was by far an all-time record year for the Israeli hi-tech industry. The report notes that the amounts invested in Israeli hi-tech is increasing, many funds are raising capital and new investors are joining in on the investments. The vast amount of capital that specifically comes from U.S. investors is of particular importance to Israeli start-ups and emerging companies, and the following ten points provide guidance for successfully navigating the U.S. venture capital market.
Continue Reading Tips for Israeli Entrepreneurs Seeking U.S. Investors